HF4493 (Legislative Session 94 (2025-2026))
Pharmacists authorized to initiate, prescribe, administer, and dispense drugs for the treatment of opioid use disorder; and grounds for disciplinary action for pharmacists and pharmacist interns modified.
Related bill: SF4486
AI Generated Summary
Purpose
- Expand the role of pharmacists to help treat opioid use disorder (OUD) by allowing them to initiate, prescribe, administer, and dispense certain medications for OUD.
- Update grounds for disciplinary action against pharmacists and pharmacist interns, clarifying and adding circumstances that can lead to sanctions or license actions.
Main provisions (what the bill would do)
- Expanded definition of who is a practitioner: Pharmacists are explicitly included as practitioners who can prescribe or administer certain medications under specific rules.
- Treatment of opioid use disorder by pharmacists:
- A pharmacist may prescribe, administer, and dispense drugs in Schedules III–V to treat OUD, if certain conditions are met (e.g., medically indicated treatment and proper documentation in the patient’s health record).
- Pharmacists must complete a training program specifically for treating substance use disorders and obtain the appropriate federal DEA registration for the schedules involved.
- Before dispensing, the pharmacist must provide counseling on proper use, follow-up needs, and any required information per state rules.
- A pharmacist cannot delegate the authority to prescribe; an intern may prepare the prescription, but a licensed pharmacist must review, approve, and sign it.
- Pharmacists may participate in initiation, management, modification, and discontinuation of OUD therapy according to a protocol or collaborative practice agreement with other licensed prescribers (e.g., dentists, physicians, physician assistants, podiatrists, veterinarians, nurse practitioners, etc.).
- Any changes in drug therapy made under a protocol must be documented in the patient’s medical record or reported to the supervising practitioner.
- Protocols and collaboration:
- The bill allows formal protocols or collaborative practice agreements to govern how pharmacists initiate, adjust, or stop therapy for OUD.
- Vaccinations and immunizations:
- Pharmacists may administer certain vaccines, including influenza and COVID-19 (or SARS-CoV-2) vaccines to eligible individuals, under specified training and reporting requirements (e.g., using the Minnesota Immunization Information Connection to check immunization status and to report administration).
- Certain supervision and training requirements apply for pharmacy technicians or interns who administer vaccines.
- Expanded clinical activities under protocol:
- Pharmacists may initiate or modify therapy for other conditions under protocols with other healthcare professionals (dentists, optometrists, physicians, physician assistants, podiatrists, veterinarians, etc.), and must document changes in the patient’s medical record.
- Controlled substances prescription rules:
- The bill updates prescription requirements for Schedule III–IV drugs to include more flexible prescribing by pharmacists under the new authority, with limits such as a maximum six-month supply and a cap on refills (up to five), subject to prescriber consent and other safeguards.
- Pharmacist authority to prescribe/dispense controlled substances (new subdivision):
- A pharmacist may prescribe, administer, and dispense controlled substances in Schedules III–V under the authority created in the bill, with the possibility for a pharmacist intern to assist under supervision.
- Other practice and safety provisions:
- Grounds for disciplinary actions include fraud, noncompliance with licensure requirements, unprofessional conduct, violations of board orders, failure to report required information, and actions that undermine patient safety or qualifying standards of care.
- The board may delay issuing a license or registration if there are pending disciplinary actions or felonies, or if related actions are underway in other states.
Significant changes to existing law
- New explicit authority for pharmacists to treat OUD with Schedule III–V medications, including required training and DEA registration.
- mandatory documentation in patient health records for changes in therapy made under protocols or collaborative agreements.
- formal inclusion of pharmacists in vaccination programs with defined supervision and training requirements.
- broad expansion of the scope of pharmacist practice through protocols and collaborations with a wider range of health professionals.
- revised grounds for disciplinary action to cover a broader set of professional conduct issues and cross-state actions.
- revised prescription rules for controlled substances to allow pharmacist-driven prescribing, administration, and dispensing under the new framework, with defined limits and reporting requirements.
Definitions and scope (important concepts)
- Opioid use disorder (OUD): The condition being treated with the expanded pharmacist role.
- Practitioner: Expanded to include pharmacists who meet the defined requirements for prescribing under this bill.
- Protocol and collaborative practice agreement: The mechanisms by which pharmacists may initiate, modify, or discontinue drug therapy in collaboration with other licensed prescribers.
- Schedules III–V: The controlled substances involved in the expanded pharmacist authority for OUD treatment, subject to training and regulatory compliance.
- DEA registration: Federal registration required for prescribing certain controlled substances.
- Counseling and health-record documentation: Required steps to ensure patient understanding and continuity of care.
Relevant Terms - opioid use disorder - pharmacist - prescribe - administer - dispense - Schedule III through V - training program (for substance use disorders) - DEA registration - protocol - collaborative practice agreement - patient health record - counseling - vaccination/immunization - Minnesota Immunization Information Connection - intramuscular and subcutaneous administration (where applicable) - opiate antagonists - self-administered hormonal contraceptives - nicotine replacement medications - HIV prevention (drug therapy to prevent HIV) - treatment plan - interdisciplinary collaboration - disciplinary action/grounds for discipline - license/registration delays or actions
Bill text versions
- Introduction PDF PDF file
Upcoming committee meetings
- Health Finance and Policy on: March 25, 2026 13:00
Actions
| Date | Chamber | Where | Type | Name | Committee Name |
|---|---|---|---|---|---|
| March 18, 2026 | House | Action | Introduction and first reading, referred to | Health Finance and Policy |
Citations
[
{
"analysis": {
"added": [],
"removed": [],
"summary": "Defines Practitioner to include a broad set of licensed health professionals, including pharmacists authorized to prescribe and administer certain medications under specified statutes.",
"modified": []
},
"citation": "151.01",
"subdivision": "subdivision 23"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Part of the cross-reference list defining practitioner scopes for sections referenced within the bill.",
"modified": []
},
"citation": "151.15",
"subdivision": "subdivision 4"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Part of the cross-reference definitions affecting practitioner scope and related clinical interpretations.",
"modified": []
},
"citation": "151.211",
"subdivision": "subdivision 3"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Part of the practitioner definition cross-reference for scope expansion.",
"modified": []
},
"citation": "151.252",
"subdivision": "subdivision 1"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Cross-reference to allow pharmacist-initiated drug therapy and related duties under protocol or collaborative practice agreements.",
"modified": []
},
"citation": "151.37",
"subdivision": "subdivision 2"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Cross-reference defining practitioner to include additional clinical roles relevant to pharmacy practice.",
"modified": []
},
"citation": "151.461",
"subdivision": ""
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Authorizes certain vaccine and immunization activities under protocol or collaborative practice agreement.",
"modified": []
},
"citation": "151.37",
"subdivision": "subdivision 14"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Authorizes vaccine-related administration by pharmacist or supervised technician as applicable.",
"modified": []
},
"citation": "151.37",
"subdivision": "subdivision 15"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Requires protocol or collaborative practice and documentation for vaccine administration.",
"modified": []
},
"citation": "151.37",
"subdivision": "subdivision 16"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Further references to prescribing or administering vaccines under supervision and reporting requirements.",
"modified": []
},
"citation": "151.37",
"subdivision": "subdivision 17"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Adds treatment of opioid use disorder under pharmacist authority with training and DEA registration prerequisites.",
"modified": []
},
"citation": "151.37",
"subdivision": "subdivision 18"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Defines additional subdivisions related to collaborative practice agreements for initiating and managing therapy.",
"modified": []
},
"citation": "151.01",
"subdivision": "27b"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Defines additional subdivisions related to the initiation and modification of drug therapy under protocols.",
"modified": []
},
"citation": "151.01",
"subdivision": "27c"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Citation within the practitioner definition referencing a special subdivision in the 2025 supplement.",
"modified": []
},
"citation": "151.01",
"subdivision": "23.1.9"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Grounds for disciplinary action related to license qualifications or misconduct, cross-referenced for pharmacists.",
"modified": []
},
"citation": "151.071",
"subdivision": "subdivision 2"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Prescription requirements for Schedule III or IV controlled substances; pharmacist prescriptive authority referenced.",
"modified": []
},
"citation": "152.11",
"subdivision": "subdivision 2"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Adds subdivision provisions allowing a pharmacist to prescribe administer and dispense Schedule III–V controlled substances under delegated authority.",
"modified": []
},
"citation": "152.12",
"subdivision": ""
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Federal law citation to the Comprehensive CLIA framework referenced in the clinical testing provisions.",
"modified": []
},
"citation": "42 U.S.C.",
"subdivision": ""
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Federal law: Clinical Laboratory Improvement Act (CLIA) referenced in testing provisions.",
"modified": []
},
"citation": "42 U.S.C. § 263a et seq.",
"subdivision": ""
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Disciplinary and reporting provisions involving sections 151.07x; cross-referenced for professional conduct.",
"modified": []
},
"citation": "151.072",
"subdivision": ""
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Investigation and cooperation provisions with the board; cross-referenced disciplinary action.",
"modified": []
},
"citation": "151.074",
"subdivision": ""
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Disciplinary grounds involving aiding or abetting suicide; referenced in board discipline provisions.",
"modified": []
},
"citation": "609.215",
"subdivision": "subdivision 1"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Disciplinary grounds with respect to chemical dependencies and related offenses; cross-referenced to board actions.",
"modified": []
},
"citation": "609.215",
"subdivision": "subdivision 2"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Reference to physician assistant prescriptive authority framework within the board's scope.",
"modified": []
},
"citation": "147A",
"subdivision": ""
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Prescribing/dispensing authority provisions for PAs or other practitioners referenced within protocols.",
"modified": []
},
"citation": "148.235",
"subdivision": ""
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Definition of opiate antagonists and related provisions cited in drug therapy and treatment protocols.",
"modified": []
},
"citation": "604A.04",
"subdivision": "subdivision 1"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Health licensing framework cross-reference for vaccination and pharmacology practice supervision.",
"modified": []
},
"citation": "62A.673",
"subdivision": "subdivision 2"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Board disciplinary action related to pharmacy practice; specific disciplinary sections cited from chapter 62J.",
"modified": []
},
"citation": "62J.842",
"subdivision": ""
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Additional disciplinary provisions for pharmacy practice under chapter 62J.",
"modified": []
},
"citation": "62J.845",
"subdivision": ""
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Cited chapter for cannabis/hemp-derived products, indicating alignment with chapter 342 applicability.",
"modified": []
},
"citation": "342",
"subdivision": ""
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Sections governing patient access to records and related health information; cross-reference in board actions.",
"modified": []
},
"citation": "144.291 to 144.298",
"subdivision": ""
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Explicit grant of authority for opioid use disorder treatment by pharmacists under the new subdivision 18.",
"modified": []
},
"citation": "151.37",
"subdivision": "subdivision 18"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Reference to specific parametric details of protocol-based drug therapy initiation/management.",
"modified": []
},
"citation": "151.01",
"subdivision": "27b"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Reference to specific parametric details of protocol-based drug therapy initiation/management.",
"modified": []
},
"citation": "151.01",
"subdivision": "27c"
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Federal law citation to Controlled Substances Act framework referenced in training and prescribing requirements.",
"modified": []
},
"citation": "21 U.S.C.",
"subdivision": ""
},
{
"analysis": {
"added": [],
"removed": [],
"summary": "Federal law: 21 U.S.C. § 823m cited for practitioner training requirements related to substance use disorder treatment.",
"modified": []
},
"citation": "21 U.S.C. § 823m",
"subdivision": ""
}
]Progress through the legislative process
In Committee